Fractyl Health, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on the stock and has a $8.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Whitney Ijem has given his Buy rating due to a combination of factors related to Fractyl Health, Inc.’s promising data from their Revita treatment. The company recently shared six-month data from the open-label REVEAL-1 cohort, which showed a significant reduction in weight regain compared to expectations after GLP-1 withdrawal. This data suggests an approximately 85% reduction in weight regain, which is encouraging despite the small study size.
Furthermore, the upcoming release of 12-month data from both the REVEAL-1 and REMAIN-1 cohorts could further solidify the treatment’s durability if results remain positive. The anticipation of controlled data expected in January 2026 also plays a role in the positive outlook. These factors combined lead to a Buy rating with a price target of $8, as the data continues to support the potential effectiveness of the Revita treatment.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.